Caballero Méndez Andy, Reynoso de La Rosa Roberto A, Abreu Bencosme Miguel E, Sosa Ortiz Mayeline N, Pichardo Beltré Eliezel, de La Cruz García Darah M, Piñero Santana Nelson J, Bacalhau de León Joana C
Molecular Biology Department, Referencia Laboratorio Clínico, Zona Industrial de Herrera, Santo Domingo Oeste, Santo Domingo, Dominican Republic.
Microbiology Department, Referencia Laboratorio Clínico, Zona Industrial de Herrera, Santo Domingo Oeste, Santo Domingo, Dominican Republic.
Bio Protoc. 2025 Apr 5;15(7):e5255. doi: 10.21769/BioProtoc.5255.
Laboratory-developed tests (LDTs) are optimal molecular diagnostic modalities in circumstances such as public health emergencies, rare disease diagnosis, limited budget, or where existing commercial alternatives are unavailable, limited in supply, or withdrawn, either temporarily or permanently. These tests reduce access barriers and enhance equitable clinical practice and healthcare delivery. Despite recommendations for the development of nucleic acid amplification tests, procedural details are often insufficient, inconsistent, and arbitrary. This protocol elucidates the methodology used in the development of a fully automated real-time polymerase chain reaction (qPCR)-based test, using the Panther Fusion Open Access functionality, for the detection of in pregnant women, using selectively enriched rectovaginal swabs. In addition, guidelines are provided for oligonucleotide design (primers and TaqMan probes), in silico and in vitro evaluation of design effectiveness, optimization of the physicochemical conditions of the amplification reaction, and result analysis based on experimental designs and acceptance criteria. Furthermore, recommendations are provided for the analytical and clinical validation of the intended use. Our approach is cost-effective, particularly during the design and optimization phases. We primarily used open-source bioinformatics software and tools for in silico evaluations for the test design. Subsequently, the process was manually optimized using a CFX96 Dx analyzer, whose technical specifications and performance are homologous to that of the final platform (Panther Fusion). Unlike Panther Fusion, the CFX96 Dx does not require excess volumes of reagents, samples, and evaluation materials (dead volume) to accommodate potential robotic handling-associated imprecisions. The utilization of the CFX96 Dx analyzer represents a strategic approach to enhancing the efficiency of resources and the optimization of time during LDT optimization. Key features • Efficient and robust use of bioinformatics tools for designing primers and TaqMan probes for qPCR-based detection of . • Optimization of physicochemical conditions and evaluation of the design effectiveness of a qPCR-based laboratory-developed test (LDT). • Analytical and clinical validation of the qPCR-based LDT developed on an open-access functionality (Open Access) of an automated in vitro diagnostic platform, Panther Fusion (Hologic).
实验室自建检测方法(LDTs)在公共卫生紧急情况、罕见病诊断、预算有限或现有商业替代检测方法不可用、供应受限或(暂时或永久)撤市等情况下,是最佳的分子诊断方式。这些检测方法减少了获取障碍,促进了公平的临床实践和医疗服务提供。尽管有关于核酸扩增检测方法开发的建议,但程序细节往往不足、不一致且随意。本方案阐明了利用Panther Fusion开放获取功能开发基于实时聚合酶链反应(qPCR)的全自动检测方法的方法,该方法用于检测孕妇中的[具体检测物],采用选择性富集的直肠阴道拭子。此外,还提供了寡核苷酸设计(引物和TaqMan探针)、设计有效性的计算机模拟和体外评估、扩增反应物理化学条件的优化以及基于实验设计和验收标准的结果分析的指南。此外,还提供了针对预期用途的分析和临床验证的建议。我们的方法具有成本效益,特别是在设计和优化阶段。我们主要使用开源生物信息学软件和工具进行检测设计的计算机模拟评估。随后,使用CFX96 Dx分析仪进行手动优化,其技术规格和性能与最终平台(Panther Fusion)同源。与Panther Fusion不同,CFX96 Dx不需要过量的试剂、样本和评估材料(死体积)来适应潜在的机器人操作相关的不精确性。CFX96 Dx分析仪的使用是一种提高资源效率和在LDT优化过程中优化时间的战略方法。关键特性 • 高效且稳健地使用生物信息学工具设计用于基于qPCR检测[具体检测物]的引物和TaqMan探针。 • 优化基于qPCR的实验室自建检测方法(LDT)的物理化学条件并评估其设计有效性。 • 对基于qPCR的LDT在自动化体外诊断平台Panther Fusion(Hologic)的开放获取功能(Open Access)上进行分析和临床验证。